Objective: The objective of this review is to examine the management strategies for
pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants …

Anticoagulant therapy is the cornerstone of therapeutic management in acute venous
thromboembolism (VTE), consisting of pulmonary embolism and deep vein thrombosis …

Background Pulmonary embolism (PE) is a potentially life‐threatening condition in which a
clot can migrate from the deep veins, most commonly in the leg, to the lungs. Conventional …

Anticoagulation therapy is mandatory in patients with pulmonary embolism to prevent
significant morbidity and mortality. The mainstay of therapy has been vitamin-K antagonist …

Venous thromboembolism (VTE) is the third most common cardiovascular disease. For most
patients, the standard of treatment has long consisted on low-molecular-weight heparin …

Pulmonary embolism (PE) is a relatively common cardiovascular emergency. PE and deep
vein thrombosis (DVT) are considered expressions of the same disease, termed as venous …

Introduction: Acute pulmonary embolism (PE) is a relatively common cardiopulmonary
emergency that is a major cause of hospitalization and morbidity and is the primary cause of …

The emergence of direct oral anticoagulants (DOACs) represents a major advancement and
paradigm shift in the treatment of venous thromboembolism. Currently, dabigatran …

Pulmonary embolism (PE), can be life-threatening without rapid appropriate therapy and
often leads to chronic disease and disability. The ambiguity of symptoms makes PE difficult …

Background Pulmonary embolism is a potentially life‐threatening condition in which a clot
can travel from the deep veins, most commonly in the leg, up to the lungs. Previously, a …